VTRS News and Press, Viatris Inc. From 09/06/23

2023-09-06 13:16:14 ET More on Viatris Seeking Alpha’s Quant Rating on Viatris Historical earnings data for Viatris Dividend scorecard for Viatris Financial information for Viatris Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs M...

2023-09-05 06:42:18 ET More on Viatris Seeking Alpha’s Quant Rating on Viatris Historical earnings data for Viatris Dividend scorecard for Viatris Financial information for Viatris Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs M...

Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV PR Newswire Tentative approval will help enhance access to WHO-recommended paediatric regimen wi...

2023-09-01 08:30:00 ET On Aug. 23, CVS Health (NYSE: CVS) announced that it's launching a new subsidiary focused on biosimilar drugs. That business, Cordavis, will start by seeking to commercialize a biosimilar to AbbVie 's blockbuster Humira. That could mean trouble on the hori...

2023-08-31 08:45:00 ET If you're wondering whether to buy Viatris (NASDAQ: VTRS) stock this fall, it's important to know the arguments for why it might gain value as well as why it's not the best option. Generic drug manufacturers can, in theory, be a reliable source of dividend...

2023-08-28 06:56:00 ET Summary The stock market, specifically the S&P 500, is still lurking over 4,400, up 16% this year. UPS is projecting to earn between $85 billion to $100 billion in revenue, just large amounts, even during a tough year that we have all been through. S...

2023-08-24 17:00:00 ET If you're looking for a high-yield dividend stock in the healthcare sector, you might be interested in comparing Takeda Pharmaceutical (NYSE: TAK) and Viatris (NASDAQ: VTRS) . Both companies offer attractive dividends, but which one is a better buy...

2023-08-24 14:12:04 ET More on generic drugmakers Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market Viatris: Turning Point For Cheap Pharma Stock Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain Novartis schedules Sandoz...

2023-08-23 13:35:09 ET More on Viatris Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market Viatris: Turning Point For Cheap Pharma Stock Viatris Q2 2023 Earnings Review: Buy, Sell, Or Hold After Mixed Results? Viatris Inc. ( VTRS ) Q2 2...

2023-08-18 13:09:45 ET Summary On August 7, Viatris released its financial results for the 2nd quarter of 2023, which, after a long time, finally managed to beat analysts' expectations. Viatris' revenue for the second quarter of 2023 was $3.92 billion, up 5.1% from the previous qu...